164 related articles for article (PubMed ID: 29801406)
1. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
2. The significance of concurrent MYC and BCL2 expression in Egyptian patients with diffuse large B-cell NHL.
Abdelhamid TM; Gaber AA; Abdelfattah RM; Algamal DA; Hamdy O; Mohamed G
Pathol Res Pract; 2024 Jan; 253():154973. PubMed ID: 38101156
[TBL] [Abstract][Full Text] [Related]
3. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
[TBL] [Abstract][Full Text] [Related]
4. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
[TBL] [Abstract][Full Text] [Related]
5. Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma.
Roh J; Yoon DH; Lee YK; Pak HK; Kim SY; Han JH; Park JS; Jeong SH; Choi YS; Cho H; Suh C; Huh J; Lee DH; Park CS
Am J Surg Pathol; 2022 Mar; 46(3):289-299. PubMed ID: 34739417
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J
Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.
de Leval L; Bonnet C; Copie-Bergman C; Seidel L; Baia M; Brière J; Molina TJ; Fabiani B; Petrella T; Bosq J; Gisselbrecht C; Siebert R; Tilly H; Haioun C; Fillet G; Gaulard P
Ann Oncol; 2012 Dec; 23(12):3143-3151. PubMed ID: 22700993
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis of diffuse large B-cell lymphoma using molecular biomarkers: a retrospective analysis from 7 Hungarian centers.
Balikó A; Szakács Z; Kajtár B; Ritter Z; Gyenesei A; Farkas N; Kereskai L; Vályi-Nagy I; Alizadeh H; Pajor L
Front Oncol; 2023; 13():1224733. PubMed ID: 37746254
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
Al-Juhaishi T; Wang Y; Milton DR; Xu-Monette ZY; Jabbour E; Daher M; Im JS; Bashir Q; Iyer SP; Marin D; Olson AL; Popat U; Qazilbash M; Rondon G; Gulbis AM; Champlin RE; Young KH; Khouri IF
Bone Marrow Transplant; 2023 Sep; 58(9):1000-1007. PubMed ID: 37198234
[TBL] [Abstract][Full Text] [Related]
10. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.
Morichika K; Karube K; Sakihama S; Watanabe R; Kawaki M; Nishi Y; Nakachi S; Okamoto S; Takahara T; Satou A; Shimada S; Shimada K; Tsuzuki T; Fukushima T; Morishima S; Masuzaki H
Am J Surg Pathol; 2021 Jun; 45(6):832-840. PubMed ID: 33899787
[TBL] [Abstract][Full Text] [Related]
11. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
Cucco F; Barrans S; Sha C; Clipson A; Crouch S; Dobson R; Chen Z; Thompson JS; Care MA; Cummin T; Caddy J; Liu H; Robinson A; Schuh A; Fitzgibbon J; Painter D; Smith A; Roman E; Tooze R; Burton C; Davies AJ; Westhead DR; Johnson PWM; Du MQ
Leukemia; 2020 May; 34(5):1329-1341. PubMed ID: 31844144
[TBL] [Abstract][Full Text] [Related]
12. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract][Full Text] [Related]
13. MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.
Gill KZ; Iwamoto F; Allen A; Hoehn D; Murty VV; Alobeid B; Bhagat G
PLoS One; 2014; 9(12):e114398. PubMed ID: 25479599
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
15. Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.
Ivanova VS; Davies J; Menter T; Wild D; Müller A; Krasniqi F; Stenner F; Papachristofilou A; Dirnhofer S; Tzankov A
Histopathology; 2024 Feb; 84(3):525-538. PubMed ID: 37965677
[TBL] [Abstract][Full Text] [Related]
16. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
Desai SH; Mwangi R; Smith AN; Maurer MJ; Farooq U; King RL; Cerhan JR; Feldman AL; Habermann TM; Thompson CA; Wang Y; Ansell SM; Witzig TE; Nowakowski GS
Hematol Oncol; 2023 Feb; 41(1):39-49. PubMed ID: 36305717
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
[TBL] [Abstract][Full Text] [Related]
18. Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning.
Tavolara TE; Niazi MKK; Feldman AL; Jaye DL; Flowers C; Cooper LAD; Gurcan MN
Diagn Pathol; 2024 Jan; 19(1):17. PubMed ID: 38243330
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters.
Filho EHCN; Zancheta SB; de Barros Silva PG; Rodríguez Burbano RM; Rabenhorst SHB
J Clin Exp Hematop; 2023; 63(3):164-172. PubMed ID: 37766562
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Czuczman MS; Trněný M; Davies A; Rule S; Linton KM; Wagner-Johnston N; Gascoyne RD; Slack GW; Brousset P; Eberhard DA; Hernandez-Ilizaliturri FJ; Salles G; Witzig TE; Zinzani PL; Wright GW; Staudt LM; Yang Y; Williams PM; Lih CJ; Russo J; Thakurta A; Hagner P; Fustier P; Song D; Lewis ID
Clin Cancer Res; 2017 Aug; 23(15):4127-4137. PubMed ID: 28381416
[No Abstract] [Full Text] [Related]
[Next] [New Search]
